Greenleaf: Most Republicans View Kennedy as Qualified to Lead HHS
Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.
After the hearings in which Senators from the Finance Committee quizzed Robert F. Kennedy Jr., the HHS secretary nominee, but before this week’s committee vote, Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, spoked with Managed Healthcare Executive about what Kennedy’s confirmation could mean for HHS, Medicare and Medicaid, and the Inflation Reduction Act.
Greenleaf said the despite Kennedy’s gaps in knowledge about Medicare and Medicaid and his controversial views about vaccine, he still has a good chance of being confirmed by the full Senate.
“Most Republicans would view [Kennedy] as being qualified, and his background and an attorney as fighting these issues that are so focused on healthcare, the way he has shaped this Make America healthy again movement. This is who President Trump wants to put in place for this position, so seems like his chances are pretty good of getting confirmed,” she said. “It would take a lot [for Republican senators] to want to go against the president.”
Regarding Medicare and Medicaid, Greenleaf suggested that Kennedy, if confirmed, would likely rely on people overseeing these programs, at least initially.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
